IVVD | tickerfilter.com

Fundamental analysis

24%

Profitability 0%

Dept financing 8%

Liquidity 75%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-16.25%

1 Month

-44.35%

3 Months

45.87%

6 Months

-26.44%

1 Year

-76.63%

2 Year

-50.24%

Key data

Stock price

$0.85

P/E Ratio

0.00

DAY RANGE

$0.77 - $0.86

EPS

-$1.29

52 WEEK RANGE

$0.35 - $4.74

52 WEEK CHANGE

-$77.08

MARKET CAP

121.831 M

YIELD

N/A

SHARES OUTSTANDING

119.443 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

1.34

PUBLIC FLOAT

AVERAGE 10 VOLUME

$3,764,556

AVERAGE 30 VOLUME

$7,095,182

Company detail

CEO: David Hering
Region: US
Website: invivyd.com
Employees: 100
IPO year: 2021

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Adagio Therapeutics focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease.

IVVD - Invivyd, Inc.